Ken Griffin Inozyme Pharma, Inc. Transaction History

Citadel Advisors LLC

$559 Billion
Q4 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Inozyme Pharma, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 2,600 shares of INZY stock, worth $2,548. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,600

Previous 3,700 29.73%

Holding current value

$2,548

Previous $19,000 63.16%

% of portfolio

0.0%

Previous 0.0%

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$2.48 - $5.54 $1.41 Million - $3.14 Million	567,349 Added 1144.77%	616,909 $1.71 Million
Q3 2024 Nov 14, 2024	BUY	$4.31 - $6.0 $101,996 - $141,990	23,665 Added 91.39%	49,560 $259,000
Q2 2024 Aug 14, 2024	SELL	$4.33 - $7.31 $289,343 - $488,476	-66,823 Reduced 72.07%	25,895 $115,000
Q1 2024 May 15, 2024	SELL	$4.14 - $7.66 $276,324 - $511,266	-66,745 Reduced 41.86%	92,718 $710,000
Q4 2023 Feb 14, 2024	BUY	$2.71 - $4.5 $68,977 - $114,538	25,453 Added 18.99%	159,463 $679,000
Q3 2023 Nov 14, 2023	SELL	$4.09 - $7.0 $47,403 - $81,130	-11,590 Reduced 7.96%	134,010 $562,000
Q2 2023 Aug 14, 2023	SELL	$4.93 - $6.74 $3.2 Million - $4.37 Million	-648,223 Reduced 81.66%	145,600 $810,000
Q1 2023 May 15, 2023	BUY	$1.3 - $5.73 $1.03 Million - $4.55 Million	793,823 New	793,823 $4.55 Million
Q3 2022 Nov 14, 2022	SELL	$2.57 - $5.45 $26,160 - $55,475	-10,179 Reduced 8.42%	110,648 $297,000
Q2 2022 Aug 15, 2022	BUY	$3.2 - $5.96 $72,096 - $134,278	22,530 Added 22.92%	120,827 $577,000
Q1 2022 May 16, 2022	SELL	$3.87 - $7.55 $33,595 - $65,541	-8,681 Reduced 8.11%	98,297 $402,000
Q4 2021 Feb 14, 2022	BUY	$5.58 - $11.5 $69,816 - $143,888	12,512 Added 13.24%	106,978 $729,000
Q3 2021 Nov 15, 2021	SELL	$11.12 - $19.4 $851,791 - $1.49 Million	-76,600 Reduced 44.78%	94,466 $1.1 Million
Q2 2021 Aug 16, 2021	SELL	$15.19 - $21.2 $1.05 Million - $1.47 Million	-69,335 Reduced 28.84%	171,066 $2.91 Million
Q1 2021 May 17, 2021	SELL	$17.77 - $27.9 $215,745 - $338,733	-12,141 Reduced 4.81%	240,401 $4.76 Million
Q4 2020 Feb 16, 2021	BUY	$19.95 - $27.55 $228,706 - $315,833	11,464 Added 4.76%	252,542 $5.21 Million
Q3 2020 Nov 16, 2020	BUY	$17.54 - $30.2 $4.23 Million - $7.28 Million	241,078 New	241,078 $6.34 Million

About Inozyme Pharma, Inc.

Ticker INZY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,145,700
Market Cap $39.3M
Description
Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, ...

More about INZY

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account